Alex Knapp is a senior editor covering healthcare, science, and cutting edge technology who joined Forbes in 2011. He's written dozens of profiles of entrepreneurs across a variety of fields and done deep dives into technological trends from superconductors to space travel to pharmaceuticals. He also co-authors the InnovationRX newsletter and edits the Under 30 lists for Science and Healthcare in both North America and Europe. He has a B.S. in biochemistry from WPI and a J.D. from the University of Kansas School of Law. Follow him across social media sites at @thealexknapp. Email him at aknapp@forbes.com
The Prototype: What Starshipโs Success Means For SpaceXโs Future
In this weekโs edition of The Prototype, we look at IBM and AMDโs plan to make quantum computing practical, why runners should strength train and more.
InnovationRx: Microsoft Cofounder Paul Allenโs Estate Launches $500 Million Fund For Research
In this weekโs edition of InnovationRx, we look at whether Congress will extend Obamacare subsidies, the latest data on Lillyโs obesity pill and more.
The Prototype: Stakes Are High For Elon Muskโs Latest Starship Test
In this weekโs edition of The Prototype, we look at new science heading to the international space station, a way to make older brains more youthful and more.
InnovationRx: Phil Knightโs $2 Billion Cancer Gift
In this weekโs edition of InnovationRx, we look at Phil Knightโs big cancer gift, Medallionโs credentialing clearinghouse, a new treatment for fibromyalgia, and more.
The Prototype: AI Tools May Degrade Doctorsโ Skills
In this weekโs edition of The Prototype, we look at the risk of depending on AI to โthinkโ for you, mass-producing satellites, helping NASA avoid space junk, and more.
InnovationRx: Shooting At The CDC Highlights The Perils Of Health Misinformation
In this weekโs InnovationRx newsletter, we look at longevity drugs for dogs, programmable mRNA for fighting cancer, AI models of living cells, and more.
Biotech Startup Tahoe Therapeutics Raised $30 Million To Build AI Models Of Living Cells
The Palo Alto, California-based company, now valued at $120 million, has developed a scalable way to quickly generate crucial biological data needed for AI modelsโand use them to find new cures for cancer.
The Prototype: This Startup Aims To Grow New Mini-Organs In Patients
In this weekโs edition of The Prototype, we look at the U.K.โs first space launch license, nuclear reactors on the Moon and more.
InnovationRx: Trump Escalates Demands That Drug Companies Lower Prices
In this weekโs edition of InnovationRx, we look at a biotech entrepreneur treating a rare genetic disease, new tech aimed at ending drug testing on animals and more.
The Wiretap: Lack Of AI Oversight Increases Data Breach Risks
Plus: why you shouldn't scrub your social media, a million dollar prize to find a WhatsApp exploit, and more.